Oct 08, 2020 10:14am EDT XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury
Sep 15, 2020 7:00am EDT XORTX Highlights New Studies of Acute Kidney Disease Due to COVID-19 Infection
Aug 31, 2020 7:00am EDT XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission
Aug 04, 2020 10:11am EDT XORTX Partners with Mount Sinai’s Icahn School of Medicine on US-based Clinical Trial in COVID-19
Jun 23, 2020 7:00am EDT XORTX Announces Mr. Anthony J. Giovinazzo to Join as Special Advisor to the Board of Directors
May 19, 2020 9:38am EDT XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs
Apr 30, 2020 9:02am EDT XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials